$4.230
-0.062 (-1.47%)At close
GCTK News
GCTK Events
GlucoTrack Inc Trading Halted, News Pending
GlucoTrack Inc trading halted, news pending
Glucotrack Subsidiary Starts GMP Production for LT-100
Lokahi Therapeutics, a subsidiary of Glucotrack, announced that it has started its initial Good Manufacturing Practice, GMP, manufacturing campaign for LT-100, the Company's lead development candidate for osteoarthritis pain. The advancement of LT-100 to GMP production marks the next step in the Company's strategy to administer LT-100 as a single subcutaneous injection per visit - a patient-centric approach compared to the 15 intradermal injections per treatment used in prior efficacy trials. "Earlier this year, we outlined our strategy to transition from 15 intradermal injections per administration to a single subcutaneous injection," said Erik Emerson, CEO of Glucotrack. "Initiating GMP manufacturing marks an important step forward as we prepare to evaluate whether this patient-friendly, non-opioid treatment approach can achieve the clinical outcomes we expect in osteoarthritis of the knee."
Lokahi Therapeutics Continues Participation in University of Georgia Program
Lokahi Therapeutics, a subsidiary of Glucotrack, announced the continued participation of the University of Georgia's Student Industry Fellows Program in the ai Futures Lab. The renewed collaboration expands Lokahi's growing nationwide network of academic institutions. "The program functions as a capital-efficient component of Lokahi's asset origination and evaluation process while providing students with direct experience addressing real-world biopharmaceutical business challenges," the company said.
Glucotrack Expands Operations of ai Futures Lab
Glucotrack announced the continued expansion of the ai Futures Lab operated through its wholly owned subsidiary, Lokahi Therapeutics. During its first year, the ai Futures Lab identified more than 45 therapeutic opportunities on a budget of approximately $33,000 and advanced five into active company discussions. These assets represent more than $500M in prior biopharmaceutical investment and include opportunities with human clinical data, positive efficacy signals, and meaningful remaining exclusivity. The ai Futures Lab is expanding from six university collaborations to 12 universities for the 2026-2027 academic year while achieving 100% retention of inaugural university partners. The pharmaceutical industry discontinues thousands of assets each year due to portfolio reprioritization, funding constraints, strategic shifts, or organizational decisions. Lokahi believes significant value remains trapped within many of these programs. The ai Futures Lab leverages strategic university partnerships and standard pharmaceutical due diligence processes to identify therapeutic assets that may be candidates for acquisition, advancement, partnering, or monetization. Students work directly with Lokahi leadership and industry experts through structured 8- to 10-week engagements, gaining real-world exposure to biopharmaceutical business development while the Company builds a continuous pipeline of late-stage asset opportunities with minimal incremental cash outlay.
Glucotrack Receives USPTO Notice of Allowance for Patent Application
Glucotrack announced that the US Patent and Trademark Office, or USPTO, has issued a notice of allowance for a patent application. The allowed claims expand the intellectual property protecting the company's continuous blood glucose monitoring platform as it advances its multi-year, fully implantable CBGM system toward commercialization. The filing adds to the three CBGM patents issued by the USPTO in late 2025, further protecting key technologies across the company's sensor architecture. The allowed claims cover implantable glucose monitoring systems that utilize an intravascular sensing lead coupled to an electronics assembly, including device architectures and methods designed to operate within the vasculature to support long-term glucose monitoring. The claims further encompass electrode configurations, lead-based sensing structures, and associated implantation methods for continuous glucose measurement.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。